Article
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Haematologica - 1 Jun 2024
Carras Sylvain, Torroja Alexia, Emadali Anouk, Montaut Emilie, Daguindau Nicolas, Tempescul Adrian, Moreau Anne, Tchernonog Emmanuelle, Schmitt Anna, Houot Roch, Dartigeas Caroline, Barbieux Sarah, Corm Selim, Banos Anne, Fouillet Ludovic, Dupuis Jehan, Macro Margaret, Fleury Joel, Jardin Fabrice, Sarkozy Clementine, Damaj Ghandi, Feugier Pierre, Fornecker Luc Matthieu, Chabrot Cecile, Dorvaux Veronique, Bouabdallah Krimo, Amorim Sandy, Garidi Reda, Voillat Laurent, Joly Bertrand, Morineau Nadine, Moles Marie Pierre, Zerazhi Hacene, Fontan Jean, Arkam Yazid, Alexis Magda, Delwail Vincent, Vilque Jean Pierre, Ysebaert Loic, Burroni Barbara, Callanan Mary, Le Gouill Steven, Gressin Rémy
Abstract excerpt
Between 2011 and 2012, a phase II trial evaluated the use of the RiBVD (rituximab, bendamustine, velcade and dexamethasone) combination as first-line treatment for mantle cell lymphoma (MCL) patients over the age of 65. We have now re-examined the classic prognostic factors, adding an assessment of TP53 mutation status. Patients (N=74; median age 73 years) were treated with the RiBVD combination. Median...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.